BACKGROUND: Strategies for initial drug therapy of hypertension are a thiazide diuretic for all or drug selection based on age/race criteria or on plasma renin activity (PRA). It is uncertain which of these strategies will achieve the highest control rate among patients with stage 1 essential hypertension. We sought to compare control rates among 3 drug selection strategies: (i) thiazide diuretic for all, (ii) thiazide diuretic for all black subjects and white subjects aged ≥50 years and a renin-angiotensin system blocker for white subjects aged <50 years, or (iii) thiazide diuretic for PRA < 0.6ng/ml/h (suppressed PRA) and a renin-angiotensin system blocker for PRA ≥ 0.6ng/ml/h (nonsuppressed PRA). METHODS: Blood pressure responses from the Genetic Epidemiology of Responses to Antihypertensives (GERA) study were used to determine control rates for each of the 3 strategies. In GERA, hypertensive adults were treated with hydrochlorothiazide (n = 286 black subjects and 284 white subjects) or with candesartan (n = 248 black subjects and 278 white subjects). RESULTS: In the overall sample, the PRA strategy was associated with the highest control rate of 69.4% vs. 61.3% with the age/race strategy (P < 0.001) and 53.8% with the thiazide for all strategy (P < 0.001). This was also true in each racial subgroup (in black subjects: 62.1% vs. 55.2% for the other 2 strategies, P = 0.02; in white subjects: 76.3% vs. 67.1% with the age/race strategy (P < 0.001) and 52.4% with the thiazide for all strategy (P < 0.001)). CONCLUSIONS: This exploratory analysis suggests that choice of initial therapy for hypertension using a PRA strategy may be associated with higher control rates than alternative strategies recommended in current guidelines.
BACKGROUND: Strategies for initial drug therapy of hypertension are a thiazide diuretic for all or drug selection based on age/race criteria or on plasma renin activity (PRA). It is uncertain which of these strategies will achieve the highest control rate among patients with stage 1 essential hypertension. We sought to compare control rates among 3 drug selection strategies: (i) thiazide diuretic for all, (ii) thiazide diuretic for all black subjects and white subjects aged ≥50 years and a renin-angiotensin system blocker for white subjects aged <50 years, or (iii) thiazide diuretic for PRA < 0.6ng/ml/h (suppressed PRA) and a renin-angiotensin system blocker for PRA ≥ 0.6ng/ml/h (nonsuppressed PRA). METHODS: Blood pressure responses from the Genetic Epidemiology of Responses to Antihypertensives (GERA) study were used to determine control rates for each of the 3 strategies. In GERA, hypertensive adults were treated with hydrochlorothiazide (n = 286 black subjects and 284 white subjects) or with candesartan (n = 248 black subjects and 278 white subjects). RESULTS: In the overall sample, the PRA strategy was associated with the highest control rate of 69.4% vs. 61.3% with the age/race strategy (P < 0.001) and 53.8% with the thiazide for all strategy (P < 0.001). This was also true in each racial subgroup (in black subjects: 62.1% vs. 55.2% for the other 2 strategies, P = 0.02; in white subjects: 76.3% vs. 67.1% with the age/race strategy (P < 0.001) and 52.4% with the thiazide for all strategy (P < 0.001)). CONCLUSIONS: This exploratory analysis suggests that choice of initial therapy for hypertension using a PRA strategy may be associated with higher control rates than alternative strategies recommended in current guidelines.
Entities:
Keywords:
blood pressure; control rate; hypertension; pharmacotherapy.
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Bryan Williams; Neil R Poulter; Morris J Brown; Mark Davis; Gordon T McInnes; John F Potter; Peter S Sever; Simon McG Thom Journal: BMJ Date: 2004-03-13
Authors: Kamel A Gharaibeh; Stephen T Turner; Abdurrahman M Hamadah; Arlene B Chapman; Rhonda M Cooper-Dehoff; Julie A Johnson; John G Gums; Kent R Bailey; Gary L Schwartz Journal: Am J Hypertens Date: 2016-06-30 Impact factor: 2.689
Authors: Mai Mehanna; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff Journal: J Clin Hypertens (Greenwich) Date: 2017-09-21 Impact factor: 3.738
Authors: Mai Mehanna; Zhiying Wang; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Kent R Bailey; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff Journal: Am J Hypertens Date: 2019-06-11 Impact factor: 3.080
Authors: Patrick N Cunningham; Zhiying Wang; Megan L Grove; Rhonda M Cooper-DeHoff; Amber L Beitelshees; Yan Gong; John G Gums; Julie A Johnson; Stephen T Turner; Eric Boerwinkle; Arlene B Chapman Journal: PLoS One Date: 2019-09-18 Impact factor: 3.240